07h45 – 08h30 | HALL A4 | Teaching Lecture: Use of Liquid Biopsies
Chair: C. Caldas
Speaker: C. Dive
08h45 – 10h15 | HALL D1 | Opening Plenary Session
Welcome by the Congress President
M. Piccart
Welcome by the ESMO President
R.A. Stahel
Message by the Chair of ECCO Patient Advisory Committee
I. Banks
Congress President
M. Piccart
Cancer research under EU Programmes and their contribution to advances in screening, palliative care and prevention
V. Andriukaitis
Genomic alterations in cancer
L.A. Garraway
Immunotherapy, past, present and future
C. Robert
10h30 – 12h20 | HALL D1 | Proffered Paper Session: Breast Cancer - Advanced Disease
Chair: A. Eniu
Chair: A.L. Børresen-Dale
1800 - Final results for overall survival (OS), the primary endpoint of the CECOG TURANDOT prospective randomised trial evaluating bevacizumab-paclitaxel (BEV-PAC) vs BEV-capecitabine (CAP) for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)
T. Brodowicz
1801 - Neoadjuvant chemotherapy with trastuzumab or lapatinib: Survival analysis of the HER2-positive cohort of the GeparQuinto study (GBG 44)
M. Untch
1802 - Overall survival (OS) from the phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) signaling inhibitor, in AR+ advanced triple-negative breast cancer (aTNBC)
J. Cortés
Discussant: F. Cardoso (Portugal)
1803 - PEGGY: A phase II randomised study of the PI3-kinase (PI3K) inhibitor pictilisib (GDC-0941) plus paclitaxel in patients (pts) with hormone receptor (HR)-positive, HER2-negative locally recurrent or metastatic breast cancer (mBC)
P. Vuylsteke
1804 - The driver landscape of breast cancer metastasis and relapse
L. Yates
1805 - Association between HER2-phenotype on circulating tumor cells and primary tumor characteristics in women with metastatic breast cancer
W. Janni
Discussant: F. Andre
10h30 – 12h20 | HALL C2 | Proffered Paper Session: Genitourinary Malignancies - Prostate Cancer
Chair: M. Hoyer
Chair: R. Cathomas
2500 - Orteronel (Ort) maintenance therapy in patients (pts) with metastatic castration resistant prostate cancer (mCRPC) and non-progressive disease after first-line docetaxel (Doc) therapy: Results of a multicenter randomized double-blind placebo-controlled phase III trial (SAKK 08/11)
S. Gillessen
2501 - A randomized, open-label, phase 2 study of enzalutamide as neoadjuvant therapy for patients undergoing prostatectomy for localized prostate cancer
B. Montgomery
2502 - TAK-385, an oral GnRH antagonist: efficacy and safety results from a randomized phase 2 trial in prostate cancer patients (pts)
N. Shore
Discussant: B. Tombal
2503 - Hypermethylation of a specific area in the TERT promoter defines a novel risk stratification biomarker for prostate cancer patients submitted to radical prostatectomy
R.A. de Mello (Portugal)
2504 - Genomic predictive and prognostic factors from plasma cell-free DNA (cfDNA) for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) commencing enzalutamide (ENZ)
K. Chi
2505 - TMPRSS2-ERG in blood and docetaxel response in metastatic castration-resistant prostate cancer
O. Reig
Discussant: H. Scher
10h30 – 12h30 | HALL A4 | Society Session: European Association for Cancer Research (EACR) - Clinical and Biological Implications of Intratumor Heterogeneity
Chair: J. Seoane
Chair: C. Caldas (Portugal)
The new genome driver-based classification of breast cancer
C. Caldas (Portugal)
Cancer genomes in the clinic
A.V. Biankin
Intratumour macro and microheterogeneity: the ultimate challenge for precision cancer medicine?
M. Gerlinger
Impact of intratumor heterogeneity in glioblastoma relapse
J. Seoane
12h45 – 14h30 | STRAUSS | Special Session: EURECCA
Chairs: C.J.H. van de Velde; R.A. Audisio
Optimising oesophageal-gastric cancer care
W. Allum
Prospective Internationl Watch and Wait Database (IWWD) for complete responders of neoadjuvant therapies for rectal cancer
N. Figueiredo (Portugal)
Breast cancer in Europe
E. Bastiaannet
13h30 – 14h30 | HALL A3 | Oncopolicy Forum: Timebombs in Oncology: Cancer Survivorship
Chair: P. Naredi
Overview of challenges facing cancer survivors
Speaker: J. Maher
Panel: J. Bremner
Panel: S. Erdem
Panel: J. Maher
Panel: L. Travado (Portugal)
Panel: A. Peterle
Concluding remarks
Chair: P. Naredi
15h15 – 16h15 | HALL A4 | Special Session: Career Opportunities for Young Oncologists in Europe
Chair: R. Califano
How to get the most out of a research fellowship abroad - medical oncology and lab opportunities?
G. Mountzios
Surgical research opportunities
J.R. Van der Vorst
Radiotherapy research opportunities
Speaker: E.C. Moser (Portugal)
16h45 – 18h05 | LEHAR 3 | Society Session: European Society of Oncology Pharmacy (ESOP)
Chair: K. Meier
ESOP-ESMO Drug shortage survey
M. Saar
ESOP-ESMO Drug shortage survey
G.J. Wiedemann
EPIC project on oral chemotherapy
A. Eberl
Pharmacovigilance in Slovenia
M. Sonc
Cytotoxic contamination project
E. Korczowska
Centres of exchange
C. Bardin
Klaus Meier Award
16h45 – 18h15 | HALL A5 | Society Session: European School of Oncology (ESO) - Is Innovation Affordable?
Chair: A. Costa
Chair: F.A. Peccatori
Economics for oncologists: The reality of costs
P. Cornes
Concerns or solutions: The ESO Innovation Task Force
M. Aapro
The World Oncology Forum: Treat the treatable
F.A. Peccatori
The ESMO initiative on affordable drugs
M. Piccart
Affordability of innovative cancer medicine: A research perspective
E. Sharpe
Industry perspective on valuation of innovation
R. Bergström
Roundtable discussion with the audience
16h50 – 18h50 | HALL D1 | Educational Symposium: What is the Optimal Endocrine Therapy in Premenopausal Women with Early Breast Cancer
Chair: F. Andre
What is the definition of an ER+ breast cancer?
J. Reis-Filho
Adjuvant endocrine therapy for a premenopausal woman with ER+ disease, considering recent results from TEXT and SOFT trials
V. Tjan-Heijnen
Unusual molecular and clinical profiles: ER+ 1-10%, ER-/PR+ and large tumours in premenopausal women
J. Bergh
Pregnancy and adjuvant endocrine therapy: Is there any window for opportunity?
S. Loibl
Discussion & Roundup
18h25 – 20h25 | STOLZ 2 | ESMO Designated Centers of Integrated Oncology and Palliative Care
19h00 – 20h30 | HALL C3 | Satellite Symposium: MSD - Checkpoint Pathway Inhibition at the Interface between Molecular Mechanisms and Patient Pathways
Welcome and Introduction
Chair: S. Agarwala
Checkpoint Pathway Inhibition to Counter Immune Evasion Across Tumor Types
S. Agarwala
Patient Pathways in Advanced Melanoma
J.J. Grob
Patient Pathways in Advanced NSCLC
J.P. Eder
Q&A and Meeting Close
Panel: All Faculty
